Vera Therapeutics Bolsters Commercial Team Ahead of Key FDA Decision for Atacicept
Vera Therapeutics elevates Matt Skelton to Chief Commercial Officer, signaling a strategic shift towards commercialization as its lead drug candidate, atacicept for IgA nephropathy, undergoes FDA Priority Review with a PDUFA date set for July 2026.